Porsche Design is proud to announce that Orlando Bloom will be the new Brand Ambassador for the brand s Timepiece and Eyewear collections. Known for his celebrated roles in numerous films and regarded as one of Hollywood s most stylish leading men, Orlando Bloom is also a long-time Porsche enthusiast. His appreciation for the exceptional design, technical innovation and functionality that define Porsche Design makes this an ideal partnership. In the new image campaign for Porsche Design, Orlando
The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform.
m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, research centers, and companies to develop scalable, personalized grafts for tissue repair.
Lakestar leads round with participation from existing investors Bessemer Venture Partners and 83North
Vertice, the spend optimization platform, today announced $50 million in Series C funding led by Lakestar. This investment brings the total raised to over $100 million. Additional participants include Perpetual Growth and CF Private Equity, alongside existing investors Bessemer Venture Partners and 83North.
This oversubscribed round is the latest milestone in Vertice s 2.5 year growth journey,
SMART Technologies and the University of Melbourne s collaborative research promise impactful ways to engage neurodivergent students.
SMART Technologies, a global leader in interactive education technology, has partnered with the University of Melbourne to launch the first-of-its-kind research initiative exploring how classroom environments can better support neurodivergent learners. The study identified key strategies and tools that promote engagement, reduce barriers, and empower these studen
– Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine
– Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields
The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research.
SEATTLE, WA, Jan 6, 2025 – (ACN Newswire) – Spectral Capital Corporation (OTCQB: FCCN), a pioneer in Quantum as a Service (QaaS) computing and decentralized cloud infrastructure, is pleased to announce the achievement of a major patent milestone as the first step in its plan to become a globally competitive leader in quantum computing patents.
"According to the World Intellectual Property Organization ("WIPO"), there were 350,000 patents filed worldwide in classical computing. An
Back to media releases (https://norgine.com/media)
Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i
As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the University of Rostock are taking water samples in all weathers. The aim is to use innovative approaches to improve wastewater treatment in Europe.
The Warnow seems to be flowing uphill on this cold morning, but it is only the wind that pushes the surface in strong gusts against the direction of flow. This part of the Warnow lies in a nature reserve. The reeds along its banks are home to valuable fa
ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) – EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to 15% of revenue, more than 46,000 employees worldwide.
– Increasingly challenging market environment for the direct-to-market segments
– Strong growth in the Semiconductor Manufacturing Technology segment
– Ou
– Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases.
– The EC approval follows a positive opinion issued on 19 October 2024 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenst
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/uploads/716035.jpg "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma")
